Achalasia Clinical Trials 2023

Achalasia Clinical Trials 2023

Achalasia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in achalasia clinical trials today.

Popular filter options for achalasia trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to achalasia

What are the top hospitals conducting achalasia research?

In the realm of clinical trials for achalasia, several esteemed hospitals are leading the way in advancing our understanding and treatment of this rare esophageal disorder. Baltimore's Johns Hopkins Hospital has been at the forefront of research, currently conducting one active trial dedicated to achalasia in addition to four completed studies. Their commitment dates back to 2014 when they recorded their first-ever trial focused on this condition. Vanderbilt University Medical Center in Nashville is also making significant strides with one ongoing achalasia trial and three previous investigations under their belt since embarking on this path in 2017.

Meanwhile, Northwestern Memorial Hospital in Chicago has entered into the field more recently but with a fervent dedication to making an impact. Currently, they have one active clinical trial for achalasia and have just begun laying the foundation for future advancements through their first recorded trial in 2020. Similarly, Emory University Hospital and Emory Saint Joseph's Hospital, both located in Atlanta, have each contributed significantly by conducting one active achalasia trial along with another previously completed study—both initiated as recently as 2021.

It is important to recognize that while these numbers may seem modest compared to other conditions or diseases studied extensively over longer periods, such concentrated efforts can yield valuable insights into a complex ailment like achalasia. These top hospitals represent beacons of hope for patients grappling with the challenges posed by this disorder—a reminder that even small steps forward contribute towards improved outcomes and quality of life for individuals affected by rare diseases like achalasia.

Which are the best cities for achalasia clinical trials?

When it comes to achalasia clinical trials, multiple cities are leading the way in research and development. Among these cities, Nashville, Atlanta, Toronto, Baltimore, and Chicago have active trials focused on various aspects of the condition. Nashville and Atlanta each offer two ongoing studies exploring treatments such as botulinum toxin and esophageal muscle biopsy. Toronto has also contributed with two active trials studying different approaches. Meanwhile, Baltimore focuses on per-oral endoscopic myotomy with fundoplication while Chicago explores short myotomy techniques. Thanks to the efforts of these cities' researchers and medical professionals, individuals affected by achalasia are provided with opportunities to participate in clinical trials aimed at improving treatment options for this challenging condition.

Which are the top treatments for achalasia being explored in clinical trials?

Current clinical trials are exploring a couple of top treatments for achalasia. One of these is short myotomy, which is currently being tested in one active trial and has been listed since 2020. Another treatment option under investigation is esophageal muscle biopsy, also involved in one ongoing trial and first listed in 2021. These innovative approaches hold promise for improving the management of achalasia, providing hope for patients suffering from this condition.

What are the most recent clinical trials for achalasia?

Recent clinical trials have been investigating innovative approaches to treat achalasia, a condition characterized by the inability of the esophagus to properly move food into the stomach. One notable trial focuses on evaluating a new treatment for achalasia in its Phase 4 stage, which became available on 3/27/2023. Another Phase 4 trial explores the potential benefits of an esophageal muscle biopsy procedure for treating achalasia and was made available on 3/17/2021. Additionally, botulinum toxin is being studied as a possible treatment option for this condition in another Phase 4 trial that began on 5/13/2019. These ongoing studies aim to enhance our understanding and management of achalasia and bring new hope to patients living with this challenging disorder.

What achalasia clinical trials were recently completed?

Recently completed clinical trials for achalasia have made significant strides in advancing our understanding and treatment options for this challenging condition. Among these groundbreaking studies, a trial sponsored by Northwestern University focused on the potential of peroral endoscopic myotomy (POEM) as a therapeutic approach. In addition, Massachusetts General Hospital conducted a trial investigating the efficacy of botulinum toxin injections in managing symptoms associated with achalasia. These recent advancements shed light on novel treatments and provide hope to individuals affected by achalasia, offering prospects for improved quality of life and better management strategies.